AR062232A1 - Compuestos antifungicos cristalinos - Google Patents

Compuestos antifungicos cristalinos

Info

Publication number
AR062232A1
AR062232A1 ARP070103473A ARP070103473A AR062232A1 AR 062232 A1 AR062232 A1 AR 062232A1 AR P070103473 A ARP070103473 A AR P070103473A AR P070103473 A ARP070103473 A AR P070103473A AR 062232 A1 AR062232 A1 AR 062232A1
Authority
AR
Argentina
Prior art keywords
crystalline forms
antifungic
crystal compounds
quinazolin
difluorophenyl
Prior art date
Application number
ARP070103473A
Other languages
English (en)
Spanish (es)
Inventor
Serra Anna Roig
Keith Lorimer
Kevin Mayer
Orpi Javier Bartroli
Paredes Antonio Canovas
Grau Elles Mollins
Original Assignee
Stiefel Laboratories
Palau Pharma Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=39082545&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=AR062232(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority claimed from EP06380225A external-priority patent/EP1887004A1/en
Priority claimed from EP07380186A external-priority patent/EP2009009A1/en
Application filed by Stiefel Laboratories, Palau Pharma Sa filed Critical Stiefel Laboratories
Publication of AR062232A1 publication Critical patent/AR062232A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/70—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
    • C07D239/72—Quinazolines; Hydrogenated quinazolines
    • C07D239/86—Quinazolines; Hydrogenated quinazolines with hetero atoms directly attached in position 4
    • C07D239/88—Oxygen atoms
    • C07D239/90—Oxygen atoms with acyclic radicals attached in position 2 or 3
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10—Antimycotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Epidemiology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
ARP070103473A 2006-08-07 2007-08-07 Compuestos antifungicos cristalinos AR062232A1 (es)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US83586306P 2006-08-07 2006-08-07
EP06380225A EP1887004A1 (en) 2006-08-07 2006-08-07 Crystalline forms of (1R,2R)-7-Chloro-3-[2-(2,4-difluorophenyl)-2-hydroxy-1-methyl-3-(1H-1,2,4-triazol-1-yl)propyl]quinazolin-4(3H)-one
US92940807P 2007-06-26 2007-06-26
EP07380186A EP2009009A1 (en) 2007-06-26 2007-06-26 Crystalline antifungal compounds

Publications (1)

Publication Number Publication Date
AR062232A1 true AR062232A1 (es) 2008-10-22

Family

ID=39082545

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP070103473A AR062232A1 (es) 2006-08-07 2007-08-07 Compuestos antifungicos cristalinos

Country Status (17)

Country Link
US (2) US7879867B2 (cg-RX-API-DMAC10.html)
EP (2) EP2049504A4 (cg-RX-API-DMAC10.html)
JP (3) JP2010513222A (cg-RX-API-DMAC10.html)
KR (1) KR20090053903A (cg-RX-API-DMAC10.html)
CN (1) CN103232442B (cg-RX-API-DMAC10.html)
AR (1) AR062232A1 (cg-RX-API-DMAC10.html)
AU (1) AU2007284851B2 (cg-RX-API-DMAC10.html)
BR (1) BRPI0716026A2 (cg-RX-API-DMAC10.html)
CA (1) CA2658843A1 (cg-RX-API-DMAC10.html)
DK (1) DK2650291T3 (cg-RX-API-DMAC10.html)
ES (1) ES2652670T3 (cg-RX-API-DMAC10.html)
IL (2) IL196722A (cg-RX-API-DMAC10.html)
IN (1) IN2014MN01560A (cg-RX-API-DMAC10.html)
MX (1) MX2009001208A (cg-RX-API-DMAC10.html)
RU (1) RU2500679C2 (cg-RX-API-DMAC10.html)
TW (1) TWI426073B (cg-RX-API-DMAC10.html)
WO (1) WO2008021049A2 (cg-RX-API-DMAC10.html)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2006018853A2 (en) 2004-08-19 2006-02-23 Hetero Drugs Limited Novel polymorphs of efavirenz
TWI363058B (en) * 2006-04-05 2012-05-01 Opko Health Inc Hydrochloride salts of 8-[{1-(3,5-bis-(trifluoromethyl)phenyl)-ethoxy}-methyl]-8-phenyl-1,7-diaza-spiro[4.5]decan-2-one and preparation process therefor
ITMI20062449A1 (it) * 2006-12-19 2008-06-20 Dipharma Spa Forma cristallina di rabeprazolo sodico
AU2010254064B2 (en) * 2009-05-29 2015-01-22 Palau Pharma, S.L.U Azole antifungal compositions
KR20120079054A (ko) * 2009-07-10 2012-07-11 에볼바 아게 디인 조성물
EP2464230B1 (en) * 2009-08-14 2016-10-05 OPKO Health, Inc. Intravenous formulations of rolapitant
US9435692B2 (en) 2014-02-05 2016-09-06 Lam Research Corporation Calculating power input to an array of thermal control elements to achieve a two-dimensional temperature output
US11039620B2 (en) 2014-02-19 2021-06-22 Corning Incorporated Antimicrobial glass compositions, glasses and polymeric articles incorporating the same
US11039621B2 (en) 2014-02-19 2021-06-22 Corning Incorporated Antimicrobial glass compositions, glasses and polymeric articles incorporating the same
US9622483B2 (en) 2014-02-19 2017-04-18 Corning Incorporated Antimicrobial glass compositions, glasses and polymeric articles incorporating the same
GB201410407D0 (en) * 2014-06-11 2014-07-23 Univ Dundee And Syngene Internat Ltd Plc And Consejo Superior De Investigaciones Cientificas And Med Treatment of chagas disease
EA025187B1 (ru) * 2015-04-17 2016-11-30 Тагир Аббасели оглы Сулейманов Производное дитиокарбамата 2-((4-(4-метилпиперазин-1-ил)фенил)амино)-2-оксоетил4-этилпиперазин-1-карбодитиоат, обладающее антифунгальной активностью
CN118695852A (zh) 2021-12-22 2024-09-24 帕劳制药有限公司 多颗粒阿巴康唑组合物

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0293500A1 (en) 1987-06-01 1988-12-07 American Cyanamid Company 3-heteroalkyl-2,4.quinzaoline-diones
GB8819308D0 (en) 1988-08-13 1988-09-14 Pfizer Ltd Triazole antifungal agents
TW218017B (cg-RX-API-DMAC10.html) 1992-04-28 1993-12-21 Takeda Pharm Industry Co Ltd
TW297813B (cg-RX-API-DMAC10.html) * 1993-09-24 1997-02-11 Takeda Pharm Industry Co Ltd
CA2134417A1 (en) * 1993-12-22 1995-06-23 Katsumi Itoh Optically active azole derivatives, their production and use
MX9702382A (es) * 1995-08-02 1998-02-28 Uriach & Cia Sa J Nuevos derivados de pirimidona con actividad antifungica.
WO1998039305A1 (en) * 1997-03-05 1998-09-11 Takeda Chemical Industries, Ltd. Crystalline form of a bis 1,2,4-triazole compound
ES2159488B1 (es) * 2000-03-07 2002-04-16 Uriach & Cia Sa J Procedimiento para la preparacion de derivados de pirimidona con actividad antifungica.

Also Published As

Publication number Publication date
AU2007284851A1 (en) 2008-02-21
US7879867B2 (en) 2011-02-01
JP2010513222A (ja) 2010-04-30
TWI426073B (zh) 2014-02-11
US20110092702A1 (en) 2011-04-21
EP2650291A1 (en) 2013-10-16
RU2500679C2 (ru) 2013-12-10
IL196722A (en) 2016-10-31
CA2658843A1 (en) 2008-02-21
WO2008021049A2 (en) 2008-02-21
EP2049504A4 (en) 2010-09-22
EP2650291B1 (en) 2017-10-04
JP2014012673A (ja) 2014-01-23
IL248216B (en) 2018-03-29
WO2008021049A9 (en) 2008-10-30
EP2049504A2 (en) 2009-04-22
TW200823197A (en) 2008-06-01
RU2009104959A (ru) 2010-08-20
IN2014MN01560A (cg-RX-API-DMAC10.html) 2015-05-08
WO2008021049A3 (en) 2008-12-31
IL196722A0 (en) 2009-11-18
ES2652670T3 (es) 2018-02-05
US8258296B2 (en) 2012-09-04
DK2650291T3 (en) 2017-10-23
MX2009001208A (es) 2009-04-14
KR20090053903A (ko) 2009-05-28
CN103232442A (zh) 2013-08-07
CN103232442B (zh) 2015-01-21
AU2007284851B2 (en) 2013-05-09
US20080076787A1 (en) 2008-03-27
BRPI0716026A2 (pt) 2013-08-06
JP2015193642A (ja) 2015-11-05

Similar Documents

Publication Publication Date Title
IN2014MN01560A (cg-RX-API-DMAC10.html)
CL2007002316A1 (es) Compuestos derivados de pirimidina, inhibidores de pi3k; composicion farmaceutica que comprende a dicho compuesto; y uso del compuesto en enfermedades proliferativas como cancer.
CL2008003023A1 (es) (s)-4-amino-n-(1-(4-clorofenil)-3-hidroxipropil)-1-(7h-pirrolo[2,3-d]pirimidin-4-il)piperidina-4-carboxamida, inhibidor de la proteina quinasa b; procedimiento de preparacion; compuestos intermediarios; composicion farmacéutica que comprende dicho compuesto; y uso para el tratamiento del cancer.
CL2007000161A1 (es) Compuestos derivados de 2,4-dioxoimidazolidina sustituida, inhibidores de proteinas cinasas; composicion farmaceutica; y uso en el tratamiento de enfermedades tales como cancer.
CL2011003266A1 (es) Compuestos derivados de imidazolidin-2-ona, con actividad inhibidora de 17alfa-hidroxilasa/liasa-c17,20; composicion farmaceutica que los comprende; y uso en el tratamiento de inflamacion o cancer, entre otras.
CL2010001368A1 (es) Compuestos derivados de 1,3-tiazina; composicion farmaceutica que lo comprende; utiles para inhibir a la beta-secretasa
CL2007000601A1 (es) Compuestos derivados de heterobiciclos pirazolicos, inhibidores de la actividad de proteina tiroxina quinasa; composicion farmaceutica que comprende dichos compuestos; y uso de los compuestos en el tratamiento de una enfermedad hiperproliferativa.
CL2008001303A1 (es) Compuestos derivados de heterociclos, moduladores de gamma secretasa; composicion farmaceutica; kit farmaceutico; y uso en el tratamiento del alzheimer.
CL2007001435A1 (es) Compuestos derivados de fenilalanina; proceso de prepatacion; composicion farmaceutica que comprende a dicho compuesto; y uso del compuesto como inhibidores de integrina para el tratamiento del cancer.
ECSP099634A (es) Derivados de piridazinona útiles como inhibidores de glucano sintasa
CL2008001633A1 (es) Compuestos derivados de pirrolidin-3-carboxamida; composición farmacéutica; y uso comominhibidores de erk para el tratamiento del cancer.
CL2007003202A1 (es) Compuestos derivados de espiroindolinona; composicion farmaceutica que comprende a dicho compuesto; y uso del compuesto para el tratamiento de trastornos de proliferacion celular.
CL2007003520A1 (es) Compuestos derivados de heterociclos sustituidos con morfolina, inhibidores de la actividad pi3 quinasa; composicion farmaceutica que comprende a dichos compuestos; kit farmaceutico; y su uso para el tratamiento profilactico o terapeutico del cancer.
CL2007001749A1 (es) Compuesto derivado de 2-arilamino-4-(heterociclo)aminopirimidina, inhibidores de la proteina quinasa c-alfa; composicion farmaceutica que comprende a dicho compuesto; y uso del compuesto en el tratamiento de diabetes, cancer, enfermedad cardiaca coronaria, aterosclerosis, entre otras.
CL2009000035A1 (es) Compuestos derivados 3-espiro-heterociclo-1il-5h-ciclopentan[d]pirimidin-indol, util para inhibir la actividad de akt quinasa; composicion farmaceutica que comprende dichos compuestos; y uso en el tratamiento de enfermedades tal como cancer, fibrosis quistica, diabetes, enfermedad de alzheimer, entre otras.
CL2009000200A1 (es) Compuestos derivados de 2,7-naftiridinas-1-ona, mediadores de syk; composicion farmaceutica; y uso en el tratamiento de una enfermedad inflamatoria, respiratoria, proliferativa celular o autoinmune.
CL2007003523A1 (es) Compuestos derivados de heterociclos sustituidos con morfolina, inhibidores de la actividad de pi3 quinasa; composicion farmaceutica que comprende a dichos compuestos; kit farmaceutico; y su uso en el tratamiento profilactico o terapeutico del cancer
BRPI0821151A2 (pt) Derivados de pirazol e uso dos mesmos como inibidores de quinases dependentes de ciclina
CL2008003200A1 (es) Compuestos derivados de tiazol, inhibidores de la proteina quinasas; composicion farmaceutica; y uso para el tratamiento del cancer, tal como cancer de vejiga, de mama y de rinon.
UY30298A1 (es) Inhibidores de la quinasa c-fms ii
CL2007003389A1 (es) Formas cristalinas de sales de acido zoledronico; composicion farmaceutica; y uso en el tratamiento del cancer.
BRPI0922642B8 (pt) formas polimórficas de sal de cloridrato de 3-(1-{3-[5-(1-metil-piperidin-4-ilmetóxi)-pirimidin-2-il]-benzil}-6-oxo-1,6-di-hidro-piridazin-3-il)-benzonitrila,seus processos de fabricação, composição farmacêutica, medicamento, e kit
CL2008002622A1 (es) 1-(1-metiletil)-4-{[4-(tetrahidro-2h-piran-4-iloxi)fenil]carbonil}piperazina y su sal hidrocloruro; formas cristalinas de la sal; proceso de preparacion; composicion farmaceutica; y uso para el tratamiento o profilaxis de deterioro cognitivo, fatiga o trastorno del sueno.
CL2006001266A1 (es) Formas solidas cristalinas i, ii, iii, iv y v de tigeciclina; procedimiento de preparacion de las formas cristalinas ii, iv y v; composicion farmaceutica que comprende las formas cristalinas; y su uso para tratar infecciones bacterianas.
CL2007002034A1 (es) Compuestos derivados de hidroximoil-tetrazol; composicion fungicida que comprende dichos compuestos uso del compuesto o la composicion para controlar de forma curativa o preventiva los hongos fitopatogenos de las plantas o cultivos;y metodo para controlar hongos pitopatogenos de plantas o cultivos.

Legal Events

Date Code Title Description
FC Refusal